MarketVIEW: Herpes simplex virus therapeutic (TX) vaccines (CAT: VAMV038)

Product Name : MarketVIEW: Herpes simplex virus therapeutic (TX) vaccines
Description : Global vaccine commercial opportunity assessment
Contents : Executive presentation (.pdf) + 1 Excel workbook (.xls)
Therapeutic Area : Novel adult vaccines
Publication date : February 2017
Catalogue No : VAMV038

Background

Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptotically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.

Vaccine manufacturers have pursued the development of both prophylactic (PX) and therapeutic (TX) HSV vaccines albeit with little success to date. For therapeutic approaches a vaccine could reduce the frequency/duration of recurrences and lessen the need for long-term pharmacotherapy. Ideally the vaccine would also reduce transmission (shedding) so having a wider public health benefit. A number of Phase II HSV TX programs operated by Genocea (GEN-003), Agenus (HerpV) and COR-1 (Admedus) have already shown in a clinical setting that a HSV TX vaccine is feasible.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a HSV therapeutic vaccine across the major Western markets to 2035. The model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, pricing/penetration estimates and revenues per competitor. LO/BASE/Hi target product profile (TPP) scenarios are included which examine the uptake of vaccines with differing clinical performance. A detailed review is also included on latest trends in disease epidemiology/dynamics and the competitive landscape.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Herpes Simplex Virus (HSV-1/2) epidemiology/vaccines and consulted with global experts regarding their predictions of vaccine deployment. Secondary source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc.

Previously published research by VacZine Analytics in the adolescent field has also been utilised.

PRODUCT CONTENTS:
Published February 2017 (CAT No: VAMV038)

****This product is composed of one Excel workbook model (.xls)1 and an executive presentation (.pdf)2

Table of Contents
Executive summary
HSV therapeutic vaccines: Commercial model: key outputs
HSV TX vaccine: total forecast value ($000s) to 2035
HSV TX vaccine: total forecast volume (000s doses) to 2035
HSV TX vaccine: LOW SCENARIO forecast value ($000s) to 2035
HSV TX vaccine: BASE SCENARIO forecast value ($000s) to 2035
HSV TX vaccine: HIGH SCENARIO forecast value ($000s) to 2035
HSV TX vaccine: forecast value ($000s) by country/region to 2035
HSV TX vaccine: forecast value ($000s) by country 5 years post-launch
HSV TX vaccine: volume (000s doses) by country/region to 2035
HSV TX: Genocea (GEN-003) $ revenues to 2035 (LO/BASE/HI)
HSV TX: Admedus (COR-1) $ revenues to 2035 (LO/BASE/HI)
HSV TX: VCL-HB01/HM01 $ revenues to 2035 (LO/BASE/HI)
Calculating TX vaccine target populations to 2035
HSV simplex virus: Disease background
HSV - the pathogen
Life cycle and pathogenesis of HSV
HSV-1 and HSV-2 life cycles
Clinical manifestations of HSV-1 and HSV-2
Association of HSV-2 and human immunodeficiency virus
Rare, deadly outcomes of HSV infection
Clinical reactivation of HSV-1 and HSV-2
Disease burden and economic burden of HSV
Summary: HSV-1/HSV-2
HSV simplex virus: Epidemiology
Epidemiology of HSV
Prevalence of HSV-2 infection in 2012 by WHO region
HSV-1/HSV-2 diagnosis
HSV surveillance
Epidemiology: UK
Epidemiology: US
Epidemiology: other markets

1 Contents available on request
2 Presentation titles may apply to more than one slide
Continued……

HSV-1 and HSV-2 seroprevalence studies
HSV-1 as an emerging cause of genital herpes
Herpes simplex virus: Current management strategies
Current management of genital herpes
2016 WHO recommendations for the treatment of genital HSV
Novel antivirals in development
Herpes simplex virus therapeutic vaccines: Rationale for development
Evidence that an HSV vaccine is feasible
Two approaches to HSV vaccination
The role of HSV TX vaccines
Questions and considerations on the efficacy of an HSV TX vaccine
HSV TX vaccines: past failures
Herpes simplex virus therapeutic vaccines: Overview of current research and development
HSV TX vaccines: overview
Overview: HSV TX vaccines in development
GEN-003 (Genocea)
HerpV (Agenus)
COR-1 (Admedus)
VCL-HB01/HM01 (Vical)
HSV529 (Sanofi)
HSV therapeutic vaccines: Commercial model assumptions
HSV target populations (scenario definition)
HSV vaccine: target product profiles
Commercial model assumptions: HSV vaccine
Markets included in the model
Commercial model assumptions
HSV vaccine segment analysis
HSV therapeutic vaccines: Quantifying HSV target populations
Calculating TX vaccine target populations
Bibliography
About VacZine Analytics
Disclaimer

Slide number = 95
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

  o FULL PRODUCT - USD $10,995/ GBP £8,940# (Region license)*

# Indicative company rate only. Prevailing rate applied to date of transaction.
* A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total
Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.
BIBLIOGRAPHY

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 813155
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009